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Abstract Mitochondrial dihydroorotate dehydrogenase (DHO-
dehase; EC 1.3.99.11) is a target of anti-proliferative, immuno-
suppressive and anti-parasitic agents. Here, redoxal, (2,2P-[3,3P-
dimethoxy[1,1P-biphenyl]-4,4P-diyl)diimino]bis-benzoic acid, was
studied with isolated mitochondria and the purified recombinant
human and rat enzyme to find out the mode of kinetic interaction
with this target. Its pattern of enzyme inhibition was different
from that of cinchoninic, isoxazol and naphthoquinone deriva-
tives and was of a non-competitive type for the human (Kic = 402
nM; Kiu = 506 nM) and the rat enzyme (Kic = 116 nM; Kiu = 208
nM). The characteristic species-related inhibition of DHOdehase
found with other compounds was less expressed with redoxal. In
human and rat mitochondria, redoxal did not inhibit NADH-
induced respiration, its effect on succinate-induced respiration
was marginal. This was in contrast to the sound effect of
atovaquone and dichloroallyl-lawsone, studied here for compar-
ison. In human mitochondria, the IC50 value for the inhibition of
succinate-induced respiration by atovaquone was 6.1 WM and
27.4 WM for the DHO-induced respiration; for dichlorallyl-
lawsone, the IC50 values were 14.1 WM and 0.23 WM.
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1. Introduction
The elucidation of the biochemical defects responsible for
certain clinical immunode¢ciencies [1] and the importance of
the de novo pyrimidine and purine nucleotide synthesis for
lymphocyte activation and proliferation [2] has stimulated in-
terest in enzymes of nucleotide metabolism as intracellular
targets for the development of immunosuppressive agents.
Isoxazol and cinchoninic acid derivatives, such as brequinar
[3,4], le£unomide, MNA715, MNA279 [5^8], have been
shown to be potent inhibitors of human dihydroorotate de-
hydrogenase (DHOdehase), the fourth enzyme of pyrimidine
de novo synthesis. Le£unomide (ARAVA1) passed clinical
trials and received approval for the treatment of rheumatoid
arthritis [5], whereas atovaquone is on clinical application
against the malaria parasite Plasmodium falciparum and Pneu-
mocystis carinii causing opportunistic infections in immuno-
suppressed patients [9,10]. Lawsone derivatives, such as di-
chloroallyl-lawsone (DCL) [11] and triazine derivatives
[8,12], were also shown to interfere with the oxidation of
DHO in mammalian cells and parasites. The ability of some
DHOdehase inhibitors to suppress virus replication, presum-
ably by lowering the intracellular pyrimidine pools, has also
been taken into strategies of therapy [13].
In mammals, the enzyme DHOdehase is located in the inner
mitochondrial membrane and intimately connected to the res-
piratory chain with ubiquinone as the proximal electron ac-
ceptor and cytochrome c oxidase (EC 1.9.3.1) as the ultimate
electron transfer system. Thereby, DHOdehase resembles
NADH dehydrogenase (EC 1.6.5.3) and succinate dehydro-
genase (EC 1.3.5.1) of the inner membrane. The other ¢ve
enzymes involved in pyrimidine de novo biosynthesis are lo-
cated in the cytosol of cells [14].
The compound redoxal, originally found by the computer
algorithm COMPARE within the National Cancer Institute’s
drug screening programme, was examined for its e¡ect on
pyrimidine biosynthesis in MOLT-4 human leukemia cells
[15]. Since the interaction of redoxal with its putative target
DHOdehase was not demonstrated with the puri¢ed enzyme
species in vitro, we initiated the present study in order to
elucidate the inhibition mechanism and to underline its attrac-
tive leadstructure for the further development of anti-pyrimi-
dine drugs.
Due to its low abundance and membrane protein nature,
su⁄ciently pure DHOdehase for inhibitor studies was very
di⁄cult to obtain until the recent availability of recombinant
rat and human DHOdehase puri¢ed from insect cells used for
heterologous overexpression [7,16]. The e¡ect of redoxal on
the puri¢ed rat enzyme was also evaluated here, because ro-
dents are taken as animal models of human diseases or me-
tabolism for in vivo testing of biologically active compounds.
In addition, we studied the e¡ects of redoxal on the respira-
tory chain activity in rat and human mitochondria in compar-
ison to the 1,4-naphthoquinone analogs DCL and atovaquone
(Fig. 1), this in order to di¡erentiate their putative e¡ect on
electron transport processes di¡erent from the DHOdehase-
catalysed oxidation of DHO to orotate.
2. Materials and methods
2.1. Material
Unless otherwise stated, all chemicals were from Boehringer Mann-
heim, Serva, Merck or Sigma, at the purest grade available. The
inhibitors studied were obtained from: redoxal ((2,2P-[3,3P-dimeth-
oxy[1,1P-biphenyl]-4,4P-diyl)diimino]bis-benzoic acid, NSC-73735)
and DCL (2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone, NSC-
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 1 1 7 - 0
*Corresponding author. Fax: (44)-6421-2864335.
E-mail: loe¥er@mailer-uni.marburg.de
1 Present address: Institute of Microbiolgy, DTU, DK-2800 Lyngby,
Denmark.
Abbreviations: DHOdehase, dihydroorotate dehydrogenase (EC
1.3.99.11); DCL, dichloroallyl-lawsone; QD, decylubiquinone;
DHO, L-dihydroorotate
FEBS 23264 28-1-00
FEBS 23264 FEBS Letters 467 (2000) 27^30
126771), NIH, Drug Synthesis and Chemistry Branch, Developmen-
tal Therapeutics Program, Division of Cancer Treatment Bethesda,
USA; atovaquone (trans-2-(4-(chlorophenyl)cyclohexyl)-3-hydroxy-
1,4-naphthoquinone), The Wellcome Foundation, Dartford, Kent,
UK. Recombinant human and rat DHOdehase were gained and pu-
ri¢ed as described previously [7,16]. Rat and human liver mitochon-
dria (human liver cells were obtained from routine histological proto-
col, Institute of Pathology, University of Marburg) were prepared
according to standard protocols [7,16]. These organelles were ‘broken’
mitochondria, due to the lack of osmotic support for intactness of the
membranes and as evidenced by high NADH oxidation [8]. These
were taken here to evaluate the e¡ect of drugs on the oxidation of
DHO, NADH and succinate, without limitation on transport or up-
take.
2.2. Enzyme assays
2.2.1. Oxygen consumption measurements. Mitochondria from the
frozen stocks were transferred to a vessel connected to a Clarke-type
electrode (Oxylab 1.81b System, Biolytik) and equilibrated for 2 min
in the incubation medium (0.07 M saccharose, 0.2 M mannitol, 1 mM
EGTA, 5 mM MgCl2, 5 mM KH2PO4, 4 mM HEPES pH 7.4).
Protein content was around 2 mg/ml for rat and 3^6 mg/ml for human
liver mitochondria. After addition of 5 mM succinate or 0.3 mM
NADH, oxygen consumption was determined amperometrically: the
inhibitors were added 1 min later. For control, the inactivation of the
£ux of electrons was achieved upon addition of 40 WM antimycin.
Stocks of redoxal and brequinar were dissolved in bu¡er; atovaquone
and DCL in DMSO with further dilution in DMSO.
2.2.2. Spectrophotometric tests. With isolated mitochondria and
1 mM DHO as substrate, DHOdehase was measured by determina-
tion of the orotate produced in the supernatant of acid-precipitated
samples at 280 nm [7]. Recombinant human and rat DHOdehase were
obtained from baculovirus-infected insect cells by puri¢cation proto-
cols described previously. The activity ratio between the recombinant
enzyme and the endogenous insect DHOdehase as determined in non-
infected cells was 240:1 and 260:1, respectively [7,16]. Co-puri¢cation
of the insect enzyme should have been negligible, because of the huge
excess of recombinant enzyme and because the binding to the cationic
exchange chromatography is expected to be di¡erent for the insect
enzyme. There are only 51% of amino acid residues similar between
the human and Drosophila melanogaster DHOdehase. Enzyme assays
were done at 30‡C according to previously described procedures using
DHO and decylubiquinone (QD) as substrates and 2,6-dichlorophe-
nol-indophenol as chromogene acceptor [7,16].
2.3. Kinetic analysis
Recent evaluation of kinetic constants for the recombinant DHO-
dehases under study gave the following values: Km = 9.4 WM (DHO),
Km = 13.7 WM (QD) for the human enzyme [7]. Km = 11.5 WM (DHO),
Km = 5.9 WM (QD) for the rat enzyme [17]. The half-maximal degree of
inhibition (IC50) for each inhibitor and the competitive (Kic) and the
uncompetitive inhibition constant (Kiu) were determined using the
equations and programmes as described previously [17,18].
3. Results and discussion
3.1. Determination of kinetic constants
The present study consolidated the substantial interference
of the compound redoxal with the oxidation of DHO to or-
otate in mammalian species. Here, the formal type of inhib-
ition of redoxal was determined with the puri¢ed recombinant
human and rat DHOdehase. For both species, a non-compet-
itive type of inhibition was deduced from enzyme kinetics for
both substrates, DHO and ubiquinone (Fig. 2). The inhibition
constants are given in Table 1; those for the human enzyme
were in the range described by Cleaveland et al. [15] who
deduced the Ki = 330 nM from Dixon plot analysis of the
DHOdehase inhibition in mitochondria of human MOLT-4
cells. The inhibition constants of redoxal for the rat enzyme
were found to be 2^3-fold lower than for the human enzyme
(Table 1). Since for the quinone co-substrate the Kic value of
116 nM was found to be only half of the Kiu value (208 nM),
the inhibition of the rat enzyme by redoxal should be classi-
¢ed as a ‘mixed type’ rather than a pure non-competitive type
of inhibition [19]. Such a mixed type of inhibition could in-
dicate that the binding of a compound involved both, the co-
substrate (quinone) binding site and the catalysis [20]. In the
case of rat DHOdehase, the inhibition pattern of redoxal re-
sembled that of brequinar. By our previous work on brequi-
nar and the rat enzyme [17], the Kic value (QD) of 42 nM was
calculated to be about 10-fold smaller than the Kiu.
As for the human DHOdehase, brequinar was shown to be
a slow binding inhibitor with an overall inhibition constant of
1.8 nM. Its high a⁄nity and characteristic interaction with the
target enzyme were proposed to be the reason for its consid-
erable side-e¡ects and narrow therapeutic window with pa-
tients [17,21]. Since the inhibition pro¢le and inhibition con-
Fig. 1. Structures of redoxal, dichlorallyl-lawsone and atovaquone.
Table 1
Type of inhibition of DHOdehase by redoxal
Species Variable substrate Constant substrate Type of inhibition Kic (nM) Kiu (nM)
Human DHO QD Non-competitive 487 þ 106 507 þ 39
QD DHO Non-competitive 402 þ 83 506 þ 29
Rat DHO QD Non-competitive 216 þ 40 233 þ 16
QD DHO Non-competitive ‘mixed type’ 116 þ 22 208 þ 13
Inhibitor constants were determined by measuring the initial velocities of the DHOdehase-catalysed reaction in the presence or absence of the
inhibitor. The velocities were determined either with varying concentrations of DHO (1.6^1000 WM) and 100 mM QD or with varying concen-
trations of QD (1.6^1000 WM) and 1 mM DHO. Inhibitor constants were derived from best ¢ts of all data and are given þ asymptotic S.E.M.
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stants of redoxal were shown here to be quite di¡erent from
that of brequinar, we would expect this new compound, or
derivatives, to be of advantage for a depression of the DHO-
dehase activity in man. We, therefore, join the call of Cleav-
land et al. [15] that this novel anti-pyrimidine drug should
merit consideration for development towards clinical trials,
as soon as possible.
With respect to the substrate DHO, redoxal was found to
be a non-competitive inhibitor of human DHOdehase (Table
1); this was in contrast to the isoxazol derivative le£unomide
(active metabolite A771726, 2-hydroxyethylidene-cyanoacetic
acid 4-tri£uoromethyl anilide), which revealed an uncompeti-
tive type of inhibition with the human enzyme [7,17]. Its in-
hibition constant was twice that of redoxal, whereas the con-
stant was 10 times smaller than that of redoxal when the
drugs were tested with the rat enzyme [16]. A considerable
di¡erence of inhibition pattern between the compound redox-
al and DCL and atovaquone, respectively, could be deduced
from the present study. By our recent work, both 1,4-naph-
thoquinone derivatives were shown to be competitive inhibi-
tors of the puri¢ed rat and human DHOdehase with respect
to the co-substrate QD [18]. DCL, with a Kic of 9.8 nM for the
human enzyme, turned out to act as a slow binding inhibitor
of the rat enzyme with an overall inhibition constant of 0.77
nM; atovaquone revealed a Kic = 2.7 WM for the human and a
Kic = 60 nM for the rat enzyme, respectively [18].
3.2. E¡ect of redoxal, DCL and atovaquone on respiratory
chain activities
Since DCL and atovaquone were reported to be inhibitors
of the mitochondrial respiratory chain in mammalian cells
and parasites [11,22,23], these compounds and redoxal were
tested here with mitochondria isolated from human and rat
liver. Table 2 gives the results from oxygen consumption
measurement with NADH, succinate and DHO as substrate.
The IC50 values for atovaquone and DCL were lower with the
mitochondrially bound rat DHOdehase than with the human
enzyme. The same tendency was observed with the puri¢ed
recombinant enzymes [18]. The IC50 values for redoxal clearly
showed it to be a speci¢c inhibitor of human (430 nM) and rat
(910 nM) DHOdehase with fairly no e¡ect on the ubiquinone
dependent succinate and NADH dehydrogenase activities. In
contrast, a considerable inhibition of the succinate oxidation
by atovaquone and DCL can be deduced from the IC50 value,
6 WM and 14 WM with human mitochondria and 1 WM and
17 WM with rat mitochondria, respectively (Table 2). A weak
e¡ect of atovaquone and DCL on the NADH oxidation was
detected. The IC50 values for atovaquone were in the same
range as those reported by Fry and Pudney [23] with rat liver
mitochondria. With human mitochondria, however, atova-
quone proved to be a less potent inhibitor of DHOdehase
than of succinate dehydrogenase. This would mean that in
human, who is the host organism for malaria parasites, ato-
vaquone would a¡ect the respiratory chain and citric acid
cycle to a greater extend than pyrimidine biosynthesis ; where-
as in the parasite P. falciparum, atovaquone seemed to inter-
fere with pyrimidine de novo synthesis to a greater extend
than with the electron transport. Our present ¢ndings on
Fig. 2. Inhibition of human and rat DHOdehase by redoxal. DHO-
dehase activity was determined with the chromogen reduction assay.
Initial velocities of human (A) and rat (C) DHOdehase as a func-
tion of one substrate concentration (DHO) at ¢xed concentrations
of the second substrate (100 WM QD). Initial velocities of human
(B) and rat (D) DHOdehase as a function of one substrate concen-
tration (QD) at ¢xed concentrations of the second substrate (1 mM
DHO). Double reciprocal plots of the data and ¢ts (solid lines)
are shown to demonstrate the type of inhibition. (A+B): b, without
inhibitor; F, 250 nM redoxal; R, 350 nM redoxal; S, 450 nM
redoxal. (C+D): a, without inhibitor; E, 100 nM redoxal; O, 200
nM redoxal; P, 300 nM redoxal.
Table 2
IC50 values for the inhibition of DHO, succinate and NADH oxidation in human and rat liver mitochondria
Species Inhibitor Substrate
DHO Succinate NADH
IC50 (WM) (n) IC50 (WM) (n) IC50 (WM) (n)
Human Atovaquone 27.4 (2) 6.1 (2) 71.5%a (2)
Mitochondria DCL 0.23 (2) 14.1 (2) 73%a (2)
Redoxal 0.43 þ 0.2 (4) 102 þ 19%a (3) 96 þ 12%a (3)
Rat Atovaquone 0.79 þ 0.28 (3) 1.2 þ 0.4 (3) 3.2 þ 1.7 (3)
Mitochondria DCL 0.013 þ 0.0002 (3) 17.5 þ 3.2 (3) 30.5 þ 8.9 (3)
Redoxal 0.91 þ 0.23 (3) 79 þ 17%a (3) 98 þ 8%a (3)
Dose response curves for inhibition were obtained by varying the drug concentration from 1 nM up to 50 WM. The concentration to give half-
maximal inhibition (IC50) was determined by ¢tting the equation v = V/(1+[I]/[IC50]) to the initial velocities. Results are means of n determina-
tions and are given þ S.D.
aAn IC50 value could not be determined within the tested range of inhibitor concentrations, therefore, the activity at the highest tested inhibitor
concentration of 50 WM is given in % of the uninhibited reaction (100%).
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the di¡erent degree of inhibition of NADH, succinate and
DHO oxidation in mitochondria by redoxal underlined the
non-competitive type of inhibition of puri¢ed DHOdehase
by this compound and the competition for the DHOdehase
quinone binding site by DCL and atovaquone.
The IC50 value for the inhibition of DHO oxidation
(Table 2) by redoxal in rat mitochondria was higher than in
human mitochondria. This seems to be in contrast to the
inhibition constants determined with the puri¢ed enzymes
(Table 1). In view of the relation between IC50 values and
the inhibition constants, the IC50 was expected to be higher
than Kic in the case of partly competitive or mixed type in-
hibition (Kic = IC50/(1+[A]/Km)) [24]. Only in the case of pure
non-competitive inhibition, the relation Kiu = Kic = IC50 holds,
as was shown here by enzyme kinetics with human DHOde-
hase in the presence of redoxal (487, 507 and 430 nM, Tables
1 and 2).
3.3. Concluding remarks
The pattern of inhibition kinetics displayed with the human
DHOdehase and redoxal di¡ers from that of all other inhib-
itors investigated in detail so far. In addition, the distinct
species-related e⁄cacy of inhibition of the human and rodent
enzyme observed with isoxazol, cinchoninic acid and naphto-
quinone derivatives [17,18] seemed to be less expressed with
redoxal. Therefore, we conclude that the binding of redoxal
may be divergent from that of le£unomide, brequinar, atova-
quone and DCL. In contrast to DCL and atovaquone, redox-
al did not interfere with respiratory chain activities. Since slow
binding inhibition was not detected with the human nor with
the rat DHOdehase, the toxic potential could be expected to
be lower than that of brequinar and DCL. Therefore, we
propose to follow redoxal as a leadstructure for the develop-
ment of a new class of pharmacological drugs with a high
speci¢city for DHOdehase and a high e⁄cacy for lowering
the pyrimidine nucleotide pools in mammalian cells.
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